Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2025)
Historic Change in Account Payables for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$2.0 million.
- Inhibikase Therapeutics' Change in Account Payables fell 53740.76% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year decrease of 21665.22%. This contributed to the annual value of $271782.0 for FY2024, which is 15388.16% up from last year.
- Per Inhibikase Therapeutics' latest filing, its Change in Account Payables stood at -$2.0 million for Q3 2025, which was down 53740.76% from $911832.0 recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Change in Account Payables peaked at $911832.0 during Q2 2025, and registered a low of -$2.0 million during Q3 2025.
- Moreover, its 5-year median value for Change in Account Payables was -$19585.0 (2023), whereas its average is -$62780.5.
- The largest annual percentage gain for Inhibikase Therapeutics' Change in Account Payables in the last 5 years was 241521.06% (2024), contrasted with its biggest fall of 110435.68% (2024).
- Over the past 5 years, Inhibikase Therapeutics' Change in Account Payables (Quarter) stood at $535977.0 in 2021, then tumbled by 30.98% to $369950.0 in 2022, then tumbled by 123.73% to -$87794.0 in 2023, then crashed by 1104.36% to -$1.1 million in 2024, then crashed by 87.58% to -$2.0 million in 2025.
- Its last three reported values are -$2.0 million in Q3 2025, $911832.0 for Q2 2025, and $680824.0 during Q1 2025.